Smaller, under-the-radar companies, backed by insider buying, presenting a compelling opportunity for investors seeking undervalued gems.

Analysts Target

Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield	Industry
H30 New	S$0.88	-3.3%	10.7%	S$702.5m	n/a	22.9	n/a	1.1%	Real Estate Management and Development
NOHO	€7.93	-1.1%	-10.5%	€166.9m	€8.80	15.9	18.0%	2.9%	Consumer Services
CDNL New	US$39.23	-34.6%	n/a	US$1.9b	US$61.00	1.2	162.4%	n/a	Capital Goods
BOTJ New	US$27.73	2.6%	98.2%	US$126.2m	n/a	1.5	n/a	1.4%	Banks
CEVI New	SEK 151.40	-0.7%	-4.7%	SEK 3.6b	SEK 175.67	28.0	17.8%	1.8%	Healthcare
Y New	CA$12.86	-1.1%	15.2%	CA$157.9m	CA$12.50	7.9	-7.1%	7.8%	Media
TPK New	UK£6.39	-4.3%	4.5%	UK£1.4b	UK£6.53	0.3	79.7%	1.9%	Capital Goods
BMRC	US$28.16	0.2%	23.4%	US$452.5m	US$31.80	1.1	102.5%	3.6%	Banks
GABC	US$50.94	2.5%	27.8%	US$1.9b	US$56.20	1.6	5.6%	2.4%	Banks
NMAN	SEK 129.80	-2.7%	-23.7%	SEK 4.5b	SEK 155.00	18.6	21.7%	3.1%	Capital Goods
PMZ.UN	CA$22.08	1.0%	46.8%	CA$2.6b	CA$25.50	1.0	31.9%	4.0%	Real Estate
CBNA New	US$47.08	-1.8%	72.7%	US$307.4m	US$49.00	1.7	10.1%	n/a	Banks
UNB	US$24.42	3.1%	-8.9%	US$121.6m	n/a	1.3	n/a	5.9%	Banks
ILPT	US$8.67	-0.8%	49.5%	US$595.4m	US$11.17	1.3	20.7%	4.6%	Real Estate
SMWB	US$8.56	15.4%	-2.3%	US$784.5m	US$10.80	2.6	117.0%	n/a	Software
SHBI	US$23.64	0.2%	48.5%	US$799.9m	US$25.75	1.3	8.1%	2.4%	Banks
RCEL	US$7.90	3.9%	42.3%	US$242.8m	US$9.03	3.2	73.2%	n/a	Pharmaceuticals & Biotech
ECEL	UK£1.19	0%	-19.7%	UK£115.9m	UK£2.05	12.1	31.7%	5.4%	Capital Goods
MATR New	CA$19.46	5.9%	78.7%	CA$1.2b	CA$23.93	38.3	41.0%	0%	Capital Goods
SFC New	CA$8.64	-2.4%	4.7%	CA$1.2b	CA$12.44	7.1	11.2%	4.8%	Insurance
SBB B	SEK 3.26	-1.5%	-33.0%	SEK 6.1b	n/a	3.1	81.3%	0%	Real Estate Management and Development
ATS New	CA$27.21	-1.1%	-28.2%	CA$2.7b	CA$39.63	55.9	49.1%	n/a	Capital Goods
PZA	CA$12.65	-0.9%	-22.5%	CA$429.3m	CA$12.00	13.9	40.0%	6.4%	Consumer Services
AUBN	US$26.26	0.4%	4.0%	US$91.5m	n/a	1.0	n/a	4.1%	Banks

Undervalued Small Caps With Insider Buying